ArticleInternational ophthalmology2019
Outer nuclear layer thickness at the central fovea relation with symptom duration in central serous chorioretinopathy.
Article in International ophthalmology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Stereopsis and Outer Retinal Structure After Reduced-Fluence Photodynamic Therapy for Central Serous Chorioretinopathy: A 12-Month Study.Ophthalmology and therapy · 2026Article
- Risk factors for the development of subretinal fluid in the fellow eyes of patients with chronic central serous chorioretinopathy.Acta ophthalmologica · 2026Article
- Construction of a prediction model for the early efficacy of 577-nm-SML in treating CSC based on Bayesian network.BMC ophthalmology · 2026Article
- Efficacy and safety of 577 nm subthreshold laser treatment in acute central serous chorioretinopathy.BMC ophthalmology · 2026Article
- Article
- OCT predictors of retinal atrophy in neovascular age-related macular degeneration treated with aflibercept.International journal of ophthalmology · 2025Article
- Changes in the outer nuclear layer and choroidal vascularity during the manifest and quiescent phases of acute central serous chorioretinopathy.Scientific reports · 2024Article
- Outer nuclear layer recovery as a predictor of visual prognosis in type 1 choroidal neovascularization of neovascular age-related macular degeneration.Scientific reports · 2023Article
- Ganglion Cell Loss in the Course of Central Serous Chorioretinopathy.Ophthalmology and therapy · 2023Article
- Morphological integrity of the outer retinal layers and visual prognosis in chronic central serous chorioretinopathy after half-dose photodynamic therapy: a qualitative SD-OCT analysis.Lasers in medical science · 2022Article
- Optical coherence tomography parameters as predictors of treatment response to a 577-nm subthreshold micropulse laser in chronic central serous chorioretinopathy.Lasers in medical science · 2021Article
- The efficacy of subthreshold micropulse yellow laser (577 nm) in chronic central serous chorioretinopathy.Lasers in medical science · 2021Article
- Dynamic changes and correlation analysis of outer retinal microstructure in macular area of central serous chorioretinopathy patients during restoration period.International ophthalmology · 2021Article
- Clinical Factors Associated with Low-Contrast Visual Acuity after Reduced-Fluence Photodynamic Therapy in Patients with Resolved Central Serous Chorioretinopathy and Good Baseline Visual Acuity.Pharmaceuticals (Basel, Switzerland) · 2021Article
- Changes in the Foveal Outer Nuclear Layer of Central Serous Chorioretinopathy Patients Over the Disease Course and Their Response to Photodynamic Therapy.Frontiers in medicine · 2021Article
- Comparison of Retinal Layer Thickness and Capillary Vessel Density in the Patients with Spontaneously Resolved Acute Central Serous Chorioretinopathy.Journal of clinical medicine · 2020Article
- Article
- 532-nm Subthreshold Micropulse Laser for the Treatment of Chronic Central Serous Retinopathy.Clinical ophthalmology (Auckland, N.Z.) · 2020Article
- The relationship between foveal outer nuclear layer thickness in the active and resolved phases of central serous chorioretinopathy treated with half-dose photodynamic therapy.BMC ophthalmology · 2019Article
- Outer Nuclear Layer as the Main Predictor to Anatomic Response to Half Dose Photodynamic Therapy in Chronic Central Serous Retinopathy.Journal of ophthalmology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo evaluate a relation between the outer nuclear layer (ONL) thickness and symptom duration in patients with central serous chorioretinopathy (CSC) using spectraldomain optical coherence tomography (SDOCT) and to compare with healthy subjects.
methodsThis retrospective study included 67 CSC patients and 20 healthy subjects. The ONL thickness was measured between internal limiting membrane and external limiting membrane at central fovea using SD-OCT (Topcon 3D OCT-2000, Japan). The patients were divided into six groups based on symptom duration: group (1) contained 14 patients (symptom duration between 1 and 30 days) , group (2) contained 11 patients (symptom duration between 31 and 60 days), group (3) contained 12 patients (symptom duration between 61 and 90 days) , group (4) contained 11 (symptom duration between 91 and 120 days), group (5) contained 7 patients (symptom duration between 121 and 150 days) and group (6) contained 12 (symptom duration between 151 days and more).
resultsThe average ONL thickness was 76.1 ± 16.8 μm in CSC in all patients and 122.4 ± 2.8 μm in healthy subjects. The major differences were between group (3) and (4) (p < 0.001). The ONL thickness was negatively correlated with symptom duration (rs = - 0.918; p< 0.001). In addition, the ONL thickness was positively correlated with BCVA (rs = 0.619; p< 0.001).
conclusionPhotoreceptor loss could begin within the first 3 months in CSC.
Indexed as
Identifiers
29916122What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.